Rapid Risk Assessment: Wound botulism among people who inject heroin in Norway
At the request of the European Commission, ECDC performed a risk assessment after six cases of wound botulism were reported in Norway among people who had injected heroin. As this is an ongoing problem, some relevant measures are proposed for consideration by other EU/EEA Member States.
As of 28 October 2013, six cases of wound botulism have been reported in Norway among people who had injected heroin. Two cases have been confirmed through mice inoculation and four are suspected cases with laboratory results pending. All cases reported heroin use and most reported intramuscular injection of heroin. They all reside in the Oslo area or in neighbouring municipalities.
The source of infection is thought to be a batch of contaminated heroin. The geographical distribution of the potentially contaminated heroin is unknown at this time, as is the distribution stage at which the heroin may have been contaminated.
The potential risk for the EU/EEA will depend on the stage of contamination. If heroin contamination occurred early in the stage of distribution, it cannot be excluded that additional wound botulism-infected heroin injectors will be identified in the EU/EEA. No person-to-person transmission has ever been reported.
Guidance on drug treatment and prevention and control of infections among people who inject drugs has recently been issued by ECDC and the EMCDDA. The two agencies will continue to monitor the evolution of this situation in terms of the epidemiological information available.
Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update
21 Jan 2021 - This risk assessment presents the latest available information on the recent emergence of three variants of concern, VOC 202012/01 identified in the United Kingdom (UK), 501Y.V2 identified in South Africa, and P.1 identified in Brazil and Japan.
Risk Assessment: Risk related to spread of new SARS-CoV-2 variants of concern in the EU/EEA
29 Dec 2020 - This risk assessment presents the latest available information on the recent emergence of two variants of potential concern, VOC 202012/01 discovered in the United Kingdom (UK) and another variant, 501.V2 identified in South Africa. It also assesses the risk of these variants of concern being introduced and spread in the EU/EEA, as well as the increased impact this would have on health systems in the coming weeks.
Threat Assessment Brief: Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom
20 Dec 2020 - Over the last few weeks, the United Kingdom (UK) has faced a rapid increase in COVID-19 cases in South East England, leading to enhanced epidemiological and virological investigations.